Patterns of infection in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) receiving 5-azacitidine. Candidates for antifungal prophylaxis

被引：0
|
作者：
Falantes, J. [1 ]
Calderon, C. [1 ]
Marquez-Malaver, F. J. [1 ]
Aguilar, M. [2 ]
Martino, M. L. [1 ]
Gonzalez, J. [1 ]
Montero, M. I. [1 ]
Parody, R. [1 ]
Espigado, I. [1 ]
Perez-Simon, J. A. [1 ]
机构：
[1] Hosp Virgen Rocio, Hematol, Inst Biomed Sevilla IBIS, Seville, Spain
[2] Hosp Virgen Rocio, Infect Dis, Seville, Spain
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70043-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-021
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [1] Patterns of Infection in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Receiving Azacitidine as Salvage Therapy. Implications for Primary Antifungal Prophylaxis
    Falantes, Jose F.
    Calderon, Cristina
    Marquez-Malaver, Francisco J.
    Aguilar-Guisado, Manuela
    Martin-Pena, Almudena
    Martino, Maria L.
    Montero, Isabel
    Gonzalez, Jose
    Parody, Rocio
    Perez-Simon, Jose A.
    Espigado, Ildefonso
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (01): : 80 - 86
  • [2] Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
    Freyrie, A.
    Reda, G.
    Vincenti, D.
    Ferla, V.
    Orofino, N.
    Sciume, M.
    Guidotti, F.
    Cortelezzi, A.
    LEUKEMIA RESEARCH, 2013, 37 : S157 - S158
  • [3] Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine
    Kuendgen, Andrea
    Mueller-Thomas, Catharina
    Urbaniak, Petra
    Lauseker, Michael
    Haferlach, Torsten
    Alpermann, Tamara
    Albuquerque, Andreia
    Kohlmann, Alexander
    Schnittger, Susanne
    Hildebrandt, Barbara
    Royer-Pokora, Brigitte
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    Goetze, Katharina
    BLOOD, 2013, 122 (21)
  • [4] Diagnostic of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Germing, Ulrich
    Haferlach, Torsten
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2015, 39 (05): : 291 - 299
  • [5] A PHASE I STUDY OF THE COMBINATION OF AZACITIDINE AND ORAL RIGOSERTIB IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR ACUTE MYELOID LEUKEMIA (AML)
    Navada, S. C.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Alvarado, Y.
    Daver, N.
    DiNardo, C.
    Konopleva, M.
    Borthakur, G.
    Azarnia, N.
    Silverman, L. R.
    LEUKEMIA RESEARCH, 2015, 39 : S45 - S45
  • [6] CONNECT MDS AND AML: THE MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML) DISEASE REGISTRY
    Steensma, D.
    Abedi, M.
    Bejar, R.
    Cogle, C.
    Foucar, K.
    Garcia-Manero, G.
    George, T.
    Grinblatt, D.
    Komrokji, R.
    Maciejewski, J.
    Pollyea, D.
    Roboz, G.
    Savona, M.
    Scott, B.
    Sekeres, M.
    Thompson, M.
    Sugrue, M.
    Swern, A.
    Nifenecker, M.
    Erba, H.
    LEUKEMIA RESEARCH, 2015, 39 : S124 - S124
  • [7] The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)
    Seymour, John F.
    Silverman, Lewis R.
    Doehner, Hartmut
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Minden, Mark D.
    Stone, Richard M.
    Lucy, Lela M.
    Songer, Stephen
    Dougherty, Donna
    Hinkle, Randy
    Gambini, Dominique
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2015, 126 (23)
  • [8] Molecular diagnostic testing patterns in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in the Connect MDS/AML Registry.
    George, Tracy
    Patel, Jay L.
    Abedi, Mehrdad
    Cogle, Christopher R.
    Erba, Harry Paul
    Garcia-Manero, Guillermo
    Grinblatt, David L.
    Kiselev, Pavel
    Komrokji, Rami S.
    Louis, Chrystal Ursula
    Maciejewski, Jaroslaw P.
    Nifenecker, Melissa
    Pollyea, Daniel Aaron
    Roboz, Gail J.
    Savona, Michael R.
    Scott, Bart L.
    Sekeres, Mikkael A.
    Steensma, David P.
    Thompson, Michael A.
    Foucar, Kathryn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)
    Laille, E.
    Ward, R.
    Nasser, A.
    Stoltz, M.
    Cogle, C.
    Gore, S.
    Skikne, B. S.
    Garcia-Manero, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Patterns of Infection in Patients with Myeloid Malignancies Receiving 5-Azacytidine: identification of Candidates for Antifungal Prophylaxis
    Calderon, Cristina
    Falantes, Jose F.
    Marquez-Malaver, Francisco
    Gonzalez, Jose
    Martino, Maria Luz
    Montero, Isabel
    Espigado, Ildefonso
    Perez-Simon, Jose Antonio
    BLOOD, 2012, 120 (21)
12345